Latest News:

SAHPRA has engaged with the Sisonke Phase 3B Implementation Study team and Janssen Pharmaceutica. The focus of the engagement was on the safety data reported from the Sisonke study, following administration of the COVID-19 vaccine Janssen, as well as the adverse events reported in the United States of America.

Based on their review of the available data, SAHPRA has recommended that the pause in the Sisonke study be lifted, provided that specific conditions are met.

Read more:https://bit.ly/3ddMDsX
#SAHPRA #Janssen #COVID19 #vaccinecovid19 ... See more

SAHPRA, together with its scientific expert committees, has recently reviewed the data from the Sisonke Phase 3b implementation study.

Press release:

SAHPRA, together with its scientific expert committees, has recently reviewed the data from the Sisonke Phase 3b implementation study. This study involves the administration of the COVID-19 vaccine Janssen, which is also referred to as the Johnson and Johnson (J&J) vaccine. Based on these data, no major safety concerns have been identified. No causal relationship between vaccination and the development of blot clots is evident at this stage.

Read more:https://bit.ly/3ddMDsX
#SAHPRA #Janssen #COVID19 #vaccinecovid19 ... See more

SAHPRA, together with its scientific expert committees, has recently reviewed the data from the Sisonke Phase 3b implementation study.

Minister of Health, Dr Zweli Mkhize today announced the temporary suspension of JnJ vaccine following FDA’s similar decision of Johnson and Johnson vaccine rollout in the United States #vaccine #VaccineRolloutSA ... See more

Watch: Ms Daphney Fafudi, Regulatory Compliance manager at SAHPRA, discusses Regulatory Compliance and overseeing Illicit medicines and products.

Ms Daphney Fafudi, Regulatory Compliance manager at SAHPRA, discusses Regulatory Compliance and overseeing Illicit medicines and products.

SAHPRA will be partnering with Bio Africa in hosting a webinar that will focus on the South African landscape and regulatory processes of IKS, Medical Cannabis and Natural Products which will help navigate South Africa’s Cannabis future.

🗓 20 April 2021
🕙 10:00 - 13:00

Registration link: https://bit.ly/3to1Nlb ... See more

Press release:

On 6 April 2021 the Pretoria High Court issued a court order pertaining to four cases that were brought against SAHPRA and the Minister of Health regarding access to Ivermectin for use in COVID-19. The court order was as a result of settlement agreements reached between SAHPRA, the Minister of Health and the applicants in the four cases.

Read more:https://bit.ly/31Zhwef
#SAHPRA #Ivermectin #courtorder #COVID19 ... See more

9 April 2021 On 6 April 2021 the Pretoria High Court issued a court order pertaining to four cases that were brought against SAHPRA and the Minister of Health regarding access to Ivermectin for use in COVID-19. The court order was as a result of... ... See more

The Government Communication and Information System in partnership with the Department of Science and Innovation, and the national Press Club will be hosting a webinar on the role of scientific research in mitigating the COVID-19 pandemic.

🗓 9 April 2021
🕙 10:30 - 11:30
Platform: Zoom
ID (964 0705 1503) Passcode (4770401)

Zoom link: https://bit.ly/2PIzjUk ... See more

Watch: The SAHPRA CEO discusses the mandate of SAHPRA

The SAHPRA CEO discusses the mandate of SAHPRA

Watch: SAHPRA CEO unpacks the process of vaccine approval

SAHPRA CEO unpacks the process of vaccine approval

Latest News:

The South African Health Products Authority (SAHPRA) registered the Covid-19 Vaccine Janssen on 31 March 2021. The registration was done in terms of Section 15(6a) of the Medicines and Related Substance Act 101 of 1965, which allows SAHPRA to register a medicine subject to certain conditions.

Read more:https://bit.ly/3dp02xh
#SAHPRA #Janssen #COVID19 #vaccinecovid19 ... See more

The South African Health Products Authority (SAHPRA) registered the Covid-19 Vaccine Janssen on 31 March 2021.